Search Result

Isoforms Recommended:	Tyk2

Results for "

Tyk2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ack1 (1) AMPK (2) Apoptosis (4) Cathepsin (1) Cytochrome P450 (2) Drug Isomer (1) FGFR (1) FLT3 (1) GSK-3 (1) HBV (1) HCV (1) HIV (3) IFNAR (7) IKK (1) Interleukin Related (9) Isotope-Labeled Compounds (6) JAK (117) JNK (1) Ligands for Target Protein for PROTAC (1) LRRK2 (2) mRNA (1) p38 MAPK (1) Phosphodiesterase (PDE) (1) PKC (1) PROTACs (3) Reference Standards (3) Small Interfering RNA (siRNA) (3) STAT (12) Syk (5) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (44) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (76) Metabolic Disease (1) Neurological Disease (3)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) mRNA (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

125

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active *TYK2* JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis ^[2].

HY-172596

TYK2 activator-1	JAK	Inflammation/Immunology
TYK2 activator-1 (16b) is a *TYK2* activator with anEC₅₀ of 1.78 μM. TYK2 activator-1 inhibits *JAK2* and JAK3 with the IC₅₀ values of 6.8 and 6.3 μM, respectively .

HY-158340

TYK2 ligand 1	JAK Ligands for Target Protein for PROTAC	Cancer
TYK2 ligand 1 is a *TYK2* ligand in the synthesis of PROTAC-based TYK2 degrader (CPD-155, HY-158142) .

HY-173359

TYK2 ligand 2	JAK	Inflammation/Immunology
TYK2 ligand 2 is a *TYK2* ligand for TYD-68 (HY-173357). TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC₅₀ value of 0.42 nM. TYD-68 can be used in the study of psoriasis .

HY-RS15300

TYK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TYK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TYK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TYK2 Human Pre-designed siRNA Set A TYK2 Human Pre-designed siRNA Set A

HY-RS15302

Tyk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tyk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tyk2 Rat Pre-designed siRNA Set A Tyk2 Rat Pre-designed siRNA Set A

HY-RS15301

Tyk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tyk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tyk2 Mouse Pre-designed siRNA Set A Tyk2 Mouse Pre-designed siRNA Set A

HY-163303

Tyk2-IN-15	JAK	Inflammation/Immunology
Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC₅₀ value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases .

HY-163304

Tyk2-IN-16	JAK	Cancer
Tyk2-IN-16 is a selective and potent *TYK2* inhibitor with an IC₅₀ of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC₅₀ of <10 nM in NK92 cells (WO2023220046A1; compound 184) .

HY-163313S

Tyk2-IN-19-d6	Isotope-Labeled Compounds	Inflammation/Immunology
Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313) .

HY-168269

Tyk2-IN-20	JAK	Cancer
Tyk2-IN-20 (Example 289) is a potent *Tyk2* inhibitor with an IC₅₀ of <5 nM. Tyk2-IN-20 als inhibits JAK1, *JAK2, and JAK3* with IIC₅₀ values of <100 nM. Tyk2-IN-20 can be used for the study of inflammatory diseases .

HY-144031S

Tyk2-IN-8	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-18709

Tyk2-IN-3	JAK	Inflammation/Immunology
Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC₅₀ of 485 nM.

HY-163305

Tyk2-IN-17	JAK	Inflammation/Immunology
Tyk2-IN-17 (compound 185) is a potent TYK2 inhibitor .

HY-161683

Tyk2-IN-19	JAK	Neurological Disease
Tyk2-IN-19 (Compound 1) is an orally active and blood-brain barrier (BBB) permeable *Tyk2* inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases .

HY-144032

Tyk2-IN-9	JAK	Inflammation/Immunology
Tyk2-IN-9 (Compound 26) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease .

HY-144087

TYK2-IN-11	JAK	Inflammation/Immunology
TYK2-IN-11 (Compound 5B) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the *JH2* structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for **Tyk2 JH2 and an IC₅₀** value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-101762

TyK2-IN-2	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective *TYK2* inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for **TYK2 JH2, IL-23 and IFNα*, respectively. TyK2-IN-2* also inhibits phosphodiesterase 4 (PDE4) with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .

HY-168339

Tyk2-IN-22	JAK	Inflammation/Immunology
Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-158692

Tyk2-IN-18	JAK	Cancer
Tyk2-IN-18 (compound 86) is a potent tyrosine kinase 2 (Tyk2) inhibitor. Tyk2-IN-18 inhibits JAK2-JH2, with an IC₅₀ of ＜10 nM ^[2].

HY-169984S

Tyk2-IN-22-d3	Isotope-Labeled Compounds STAT JAK	Inflammation/Immunology
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation ^[2].

HY-150720

TYK2-IN-12	JAK IFNAR	Inflammation/Immunology
TYK2-IN-12 (compound 30) is an orally active, potent and selective *TYK2* (tyrosine kinase 2) inhibitor, with a K_i of 0.51 nM. TYK2-IN-12 inhibits IL-12 induced IFNγ, with IC₅₀ values of 2.7 and 7.0 μM in human and mouse whole blood, respectively. TYK2-IN-12 can be used for psoriasis research .

HY-163312S

Tyk2-IN-18-d5	JAK	Inflammation/Immunology
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-163314S

Tyk2-IN-18-d3	JAK Interleukin Related IFNAR	Inflammation/Immunology
Tyk2-IN-18-d3 (Compound 18) is a *Tyk2* inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

HY-169986S

TyK2-IN-21-d3	JAK	Inflammation/Immunology
TyK2-IN-21-d3 (Compound 3c) is the orally active prodrug of the tyrosine kinase 2. TyK2-IN-21-d3 exhibits good chemical stability in aqueous system under different pHs. TyK2-IN-21-d3 alleviates the effect of gastric acid changes on drug absorption and improve the drug bioavailability in rat model .

HY-138317

Tyk2-IN-10	JAK	Cancer
Tyk2-IN-10 (compound 17.5) is a tyrosine kinase 2-mediated signaling inhibitor involved in inflammation regulation .

HY-149892S

TYK2 JH2-IN-1-d3	JAK	Cancer
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-158142

*PROTAC TYK2* degrader-1**	PROTACs JAK	Cancer
PROTAC TYK2 degrader-1 (CPD-155) is a PROTAC targeting degrader to *TYK2* with D_max >60%. (Structure Note: PINK, TYK2 ligand 1 (HY-158340); Blue, VHL ligand Thalidomide (HY-14658); Black, linker)

HY-152227

*PROTAC TYK2* degradation agent1**	PROTACs JAK	Inflammation/Immunology
PROTAC TYK2 degradation agent1 is a potent and subtype-selective *TYK2* degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC₅₀ value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease .

HY-143884

*JAK2/TYK2-IN-1*	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2/TYK2-IN-2* has anti-inflammatory activity .

HY-161019

*JAK1/TYK2-IN-4*	JAK	Inflammation/Immunology
JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC₅₀s of 39 nM and 21 nM, respectively. JAK1/TYK2-IN-4 has oral bioavailability .

HY-175983

*JAK1/TYK2-IN-5*	JAK	Cancer
JAK1/TYK2-IN-5 (compound A1) is a *JAK1/TYK2* inhibitor with K_i values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .

HY-145336

*JAK1/TYK2-IN-1*	JAK	Cancer
JAK1/TYK2-IN-1 is a dual inhibitor of *TYK2* and JAK1 (IC₅₀ = 29 and 41 nM respectively).

HY-143885

*JAK1/TYK2-IN-3*	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual *TYK2/JAK1* inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to *JAK2* (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related *TYK2/JAK1*-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .

HY-153103

*LRRK2/NUAK1/TYK2-IN-1*	LRRK2 JAK AMPK	Inflammation/Immunology
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), *TYK2* and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable *TYK2* inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable *TYK2* inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-150096

Zasocitinib 1 Publications Verification NDI-034858; TAK-279	JAK	Inflammation/Immunology
Zasocitinib (NDI-034858) is a *TYK2* inhibitor, target **TYK2 JH2** domain with binding constant K_d of <200 pM .

HY-153058

LRRK2-IN-8	LRRK2 JAK AMPK	Neurological Disease Cancer
LRRK2-IN-8 is a *LRRK2* inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits *TYK2* and NUAK1 with IC₅₀s of 10-100 nM .

HY-156409

ABBV-712	JAK	Inflammation/Immunology
ABBV-712 is a selective and orally active inhibitor of Tyrosine kinase 2 (TYK2). ABBV-712 has EC₅₀ values of 0.01, 0.19, and 0.17 μM for **TYK2 JH2*, TYK2* cells and human whole blood, respectively. ABBV-712 has anti-inflammatory activity and can be used in the research of autoimmune diseases .

HY-152080

Blovacitinib TUL01101	JAK	Inflammation/Immunology
Blovacitinib (TUL01101) is a potent, selective and orally active JAK1 inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Blovacitinib can be used for the research of rheumatoid arthritis .

HY-131968

BMS-986202 1 Publications Verification	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active *Tyk2* inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-175310S

Voderdeucitinib	JAK	Inflammation/Immunology
Voderdeucitinib (Compoudn I) is a *TYK2* inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .

HY-19631B

Ilginatinib hydrochloride 1 Publications Verification NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631A

Ilginatinib 1 Publications Verification NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate 1 Publications Verification NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-177131

Soficitinib	JAK	Inflammation/Immunology
Soficitinib (Compound 20) is a selective inhibitor targeting tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) with an IC₅₀ values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases .

HY-177130S

Socrodeucitinib	JAK	Inflammation/Immunology
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-117287

Deucravacitinib Maximum Cited Publications 31 Publications Verification BMS-986165	JAK Interleukin Related IFNAR Isotope-Labeled Compounds	Inflammation/Immunology
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric *TYK2* inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis ^[2].

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

613 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 613 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Species:	Human (3)
Tag:	His (3) Avi (1) Flag (1)
Source:	sf9 insect cells (1) Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P704967

	TYK2 Protein, Human (sf9, His) Tyk2; tyrosine kinase 2; non-receptor tyrosine-protein kinase Tyk2; JTK1	Human	sf9 insect cells

HY-P702722

	TYK2 Protein, Human (Biotinylated, sf9, His, Flag, Avi) Tyk2; tyrosine kinase 2; non-receptor tyrosine-protein kinase Tyk2; JTK1	Human	Sf9 insect cells
	TYK2 Protein, Human (Biotinylated, sf9, His, Flag, Avi) is the recombinant human-derived TYK2, expressed by Sf9 insect cells , with His, Avi, Flag labeled tag. ,

HY-P704172

	TYK2 Protein, Human (316a.a, sf9, His) Tyk2; tyrosine kinase 2; non-receptor tyrosine-protein kinase Tyk2; JTK1	Human	Sf9 insect cells
	TYK2 Protein, Human (Active, sf9, His) is the recombinant human-derived TYK2 protein, expressed by Sf9 insect cells, with N-His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis ^[2].

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-131968

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-163313S

Tyk2-IN-19-d6
Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313) .

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation ^[2].

HY-163312S

Tyk2-IN-18-d5
Tyk2-IN-18-d5 (Compound 13) is the deuterated *TYK2* inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .

HY-163314S

Tyk2-IN-18-d3
Tyk2-IN-18-d3 (Compound 18) is a *Tyk2* inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

HY-149892S

TYK2 JH2-IN-1-d3
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-175310S

Voderdeucitinib
Voderdeucitinib (Compoudn I) is a *TYK2* inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .

HY-177130S

Socrodeucitinib

Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-117287

Deucravacitinib

30+ Cited Publications

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis ^[2].

HY-160144S

Lomedeucitinib
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor ^[2] .

HY-160144S2

(rac)-Lomedeucitinib
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus ^[2] .

HY-160144S1

(S)-Lomedeucitinib
(S)-Lomedeucitinib ((S)-BMS-986322) is a S-enantiomer of Lomedeucitinib (HY-160144S). Lomedeucitinib is a tyrosine protein kinase (TYK2) inhibitor .

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-103018S

Gusacitinib-d4

Gusacitinib-d₄ (ASN-002-d₄) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma ^[2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P85402

	Tyk 2 Antibody (YA5094) Tyk2; Non-receptor tyrosine-protein kinase Tyk2	WB, ELISA	Human
	Tyk 2 Antibody (YA5094) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Tyk 2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-172596

TYK2 activator-1		Alkynes
TYK2 activator-1 (16b) is a *TYK2* activator with anEC₅₀ of 1.78 μM. TYK2 activator-1 inhibits *JAK2* and JAK3 with the IC₅₀ values of 6.8 and 6.3 μM, respectively .

Cat. No.	Product Name		Classification

HY-RS15300

TYK2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TYK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TYK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15302

Tyk2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Tyk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15301

Tyk2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Tyk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tyk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174638

Human IL13RA1 mRNA		mRNA
Human IL13RA1 mRNA encodes the human interleukin 13 receptor subunit alpha 1 (IL13RA1) protein, a subunit of the interleukin 13 receptor. IL13RA1 serves as a primary IL13-binding subunit of the IL13 receptor, and may also be a component of IL4 receptors. It has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: